J
Jeanne M. Clark
Researcher at Johns Hopkins University School of Medicine
Publications - 261
Citations - 31356
Jeanne M. Clark is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Type 2 diabetes & Weight loss. The author has an hindex of 68, co-authored 229 publications receiving 26900 citations. Previous affiliations of Jeanne M. Clark include Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Arun J. Sanyal,Naga Chalasani,Kris V. Kowdley,Arthur J. McCullough,Anna Mae Diehl,Nathan M. Bass,Brent A. Neuschwander-Tetri,Joel E. Lavine,James Tonascia,Aynur Unalp,Mark L. Van Natta,Jeanne M. Clark,Elizabeth M. Brunt,David E. Kleiner,Jay H. Hoofnagle,Patricia R. Robuck +15 more
TL;DR: Vitamin E was superior to placebo for the treatment of nonalcoholic steatohepatitis in adults without diabetes, and significant benefits of pioglitazone were observed for some of the secondary outcomes.
Journal ArticleDOI
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.
Rena R. Wing,Paula Bolin,Frederick L. Brancati,George A. Bray,Jeanne M. Clark,Mace Coday,Richard S. Crow,Jeffrey M. Curtis,Caitlin Egan,Mark A. Espeland,Mary Evans,John P. Foreyt,Siran Ghazarian,Edward W. Gregg,Barbara Harrison,Helen P. Hazuda,James O. Hill,Edward S. Horton,S. Van Hubbard,John M. Jakicic,Robert W. Jeffery,Karen C. Johnson,Steven E. Kahn,Abbas E. Kitabchi,William C. Knowler,Cora E. Lewis,Barbara J. Maschak-Carey,Maria G. Montez,Anne Murillo,David M. Nathan,Jennifer Patricio,Anne L. Peters,Xavier Pi-Sunyer,Henry J. Pownall,David M. Reboussin,Judith G. Regensteiner,Amy D. Rickman,Donna H. Ryan,Monika M. Safford,Thomas A. Wadden,Lynne E. Wagenknecht,Delia Smith West,David F. Williamson,Susan Z. Yanovski +43 more
TL;DR: An intensive lifestyle intervention focusing on weight loss did not reduce the rate of cardiovascular events in overweight or obese adults with type 2 diabetes.
Journal ArticleDOI
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri,Rohit Loomba,Arun J. Sanyal,Joel E. Lavine,Mark L. Van Natta,Manal F. Abdelmalek,Naga Chalasani,Srinivasan Dasarathy,Anna Mae Diehl,Bilal Hameed,Kris V. Kowdley,Arthur J. McCullough,Norah A. Terrault,Jeanne M. Clark,James Tonascia,Elizabeth M. Brunt,David E. Kleiner,Edward Doo +17 more
TL;DR: Obeticholic acid improved the histological features of non-alcoholic steatohepatitis, but its long-term benefits and safety need further clarification.
Journal ArticleDOI
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes: One-Year Results of the Look AHEAD Trial
Mark A. Espeland,Xavier Pi-Sunyer,George L. Blackburn,Frederick L. Brancati,George A. Bray,Renee Bright,Jeanne M. Clark,Jeffrey M. Curtis,John P. Foreyt,Kathryn Graves,Steven M. Haffner,Barbara Harrison,James O. Hill,Edward S. Horton,John M. Jakicic,Robert W. Jeffery,Karen C. Johnson,Steven E. Kahn,David E. Kelley,Abbas E. Kitabchi,William C. Knowler,Cora E. Lewis,Barbara J. Maschak-Carey,Brenda Montgomery,David M. Nathan,Jennifer Patricio,Anne L. Peters,J. Bruce Redmon,Rebecca S. Reeves,Donna H. Ryan,Monika M. Safford,Brent Van Dorsten,Thomas A. Wadden,Lynne E. Wagenknecht,Jacqueline Wesche-Thobaben,Rena R. Wing,Susan Z. Yanovski +36 more
TL;DR: At 1 year, ILI resulted in clinically significant weight loss in people with type 2 diabetes and was associated with improved diabetes control and CVD risk factors and reduced medicine use in ILI versus DSE.
Journal ArticleDOI
The prevalence and etiology of elevated aminotransferase levels in the United States.
TL;DR: Aminotransferase elevation was common in the United States, and the majority could not be unexplained by alcohol consumption, viral hepatitis or hemochromatosis, and thus may represent nonalcoholic fatty liver disease.